Literature DB >> 2539872

Determination of delta 1-tetrahydrocannabinol in human fat biopsies from marihuana users by gas chromatography-mass spectrometry.

E Johansson1, K Norén, J Sjövall, M M Halldin.   

Abstract

A gas chromatographic-mass spectrometric (GC/MS) method for analysis of delta 1-tetrahydrocannabinol (delta 1-THC) in human fat samples is described. The fat sample, obtained from heavy marihuana users 1 week before and 4 weeks after smoking, is homogenized in hexane + 2-propanol, centrifuged, and the supernatant mixed with Lipidex 5000. The solvent is evaporated and the dried gel is packed in a glass column. delta 1-THC is eluted from the column with methanol + water + acetic acid, diluted with water and the eluent is passed through a bed of Octadecylsilane-bonded silica. After washing and drying, the retained delta 1-THC is eluted with hexane, derivatized with N-methyl-N-(t-butyl-dimethysilyl)trifluoroacetamide (MTBSTFA) and finally purified by HPLC on an Octadecyl Sl 100 column in methanol. The amount of delta 1-THC is determined by GC/MS, using selected ion monitoring, and a deuterated internal standard. The recovery of delta 1-THC is about 80%, and the concentration of delta 1-THC in the fat samples analysed ranged between 0.4 and 193 ng/g wet tissue.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2539872     DOI: 10.1002/bmc.1130030109

Source DB:  PubMed          Journal:  Biomed Chromatogr        ISSN: 0269-3879            Impact factor:   1.902


  29 in total

1.  Perinatal exposure to Δ9-tetrahydrocannabinol triggers profound defects in T cell differentiation and function in fetal and postnatal stages of life, including decreased responsiveness to HIV antigens.

Authors:  Catherine Lombard; Venkatesh L Hegde; Mitzi Nagarkatti; Prakash S Nagarkatti
Journal:  J Pharmacol Exp Ther       Date:  2011-08-10       Impact factor: 4.030

Review 2.  Human cannabinoid pharmacokinetics.

Authors:  Marilyn A Huestis
Journal:  Chem Biodivers       Date:  2007-08       Impact factor: 2.408

Review 3.  Cannabinoids in clinical practice.

Authors:  E M Williamson; F J Evans
Journal:  Drugs       Date:  2000-12       Impact factor: 9.546

4.  Can oral fluid cannabinoid testing monitor medication compliance and/or cannabis smoking during oral THC and oromucosal Sativex administration?

Authors:  Dayong Lee; Erin L Karschner; Garry Milman; Allan J Barnes; Robert S Goodwin; Marilyn A Huestis
Journal:  Drug Alcohol Depend       Date:  2012-11-10       Impact factor: 4.492

5.  Urinary 11-nor-9-carboxy-tetrahydrocannabinol elimination in adolescent and young adult cannabis users during one month of sustained and biochemically-verified abstinence.

Authors:  Randi Melissa Schuster; Kevin Potter; Ryan Vandrey; Maya Hareli; Jodi Gilman; David Schoenfeld; A Eden Evins
Journal:  J Psychopharmacol       Date:  2019-09-19       Impact factor: 4.153

6.  Terminal elimination plasma half-life of delta 1-tetrahydrocannabinol (delta 1-THC) in heavy users of marijuana.

Authors:  E Johansson; M M Halldin; S Agurell; L E Hollister; H K Gillespie
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

Review 7.  Pharmacokinetics and pharmacodynamics of cannabinoids.

Authors:  Franjo Grotenhermen
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

8.  Postmortem redistribution of THC in the pig.

Authors:  Bertrand Brunet; Thierry Hauet; William Hébrard; Yves Papet; Gérard Mauco; Patrick Mura
Journal:  Int J Legal Med       Date:  2010-01-07       Impact factor: 2.686

9.  Δ(9)-Tetrahydrocannabinol disrupts estrogen-signaling through up-regulation of estrogen receptor β (ERβ).

Authors:  Shuso Takeda; Kazutaka Yoshida; Hajime Nishimura; Mari Harada; Shunsuke Okajima; Hiroko Miyoshi; Yoshiko Okamoto; Toshiaki Amamoto; Kazuhito Watanabe; Curtis J Omiecinski; Hironori Aramaki
Journal:  Chem Res Toxicol       Date:  2013-06-11       Impact factor: 3.739

10.  Impact of prolonged cannabinoid excretion in chronic daily cannabis smokers' blood on per se drugged driving laws.

Authors:  Mateus M Bergamaschi; Erin L Karschner; Robert S Goodwin; Karl B Scheidweiler; Jussi Hirvonen; Regina H C Queiroz; Marilyn A Huestis
Journal:  Clin Chem       Date:  2013-03       Impact factor: 8.327

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.